CSL

0.11%

$288.93 csl limited

Ann: Appendix 4D and Half Year Accounts, page-23

First 23 Last

Share
Profile

Follow
zaidi675

407 Posts.

21

14/02/19

00:40

Post #: 37430456
Share

Originally posted by madamswer: ↑

"Hi Adam,
I wonder if you are able to suggest what will be a reasonable entry price for someone who never held CSL before? I still do not believe why I did not buy it when it nearly touched $100 an Year or two ago. While it may never go that down but is it a reasonable value below 170?"

As you might know, I am a mad keen fan of this company and consider it to be the best quality ASX-listed company, for a host of reasons.

But I would not buy CSL at the current price, despite it being a truly wonderful business.

The reason lies in the investing adage of:

"Quality is what you buy; Value is what you get."

And in CSL's case, you are buying quality in spades, but at the current valuation multiple of around 30 times [*], you aren't getting much value.

[*] It warrants mentioning that CSL's earnings a significantly understated given the company expenses all of its ~US$800m of R&D expenditure. And $800m is highly significant in the context of a Pre-Tax Profit figure of around US$2.5bn. It stands to reason that, if CSL capitalised, say, half of its R&D spend (which the majority of other companies in CSL's situation would do), the company's Pre-Tax Profit would rise by a full one-third and the ensuing P/E multiple would be closer to 23 times which, while not 30 times, is still not cheap.

There is precious little valuation buffer or margin of safety inherent in the current stock price.

In my experience, every 4 or 5 years some extraneous factor - could be a regulatory scare, a trial that disappoints, the A$ strengthening, weaker-than-expected guidance or a financial market crisis - which causes CSL's share price to fall dramatically to a level that makes it attractive enough to buy.

My Rule of Thumb, which has served me well with CSL, is that I add to my holdings in the stock every time the "raw" P/E multiple falls below 25 times (i.e., when the P/E multiple, adjusted for excess R&D expense, falls to 17x or 18x.

..

Expand

As always, sincere thanks for not only providing some guidance but the thought process behind the working of it.

CSL Price at posting: $186.09 Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 11 more messages in this thread...

First 23 Last

Add CSL (ASX) to my watchlist

(20min delay)
Last $288.93		Change 0.320(0.11%)		Mkt cap ! $139.9B

Open	High	Low	Value	Volume
$287.64	$289.70	$287.16	$174.5M	601.5K

Buyers (Bids)

No.	Vol.	Price($)
1	149	$288.79

Sellers (Offers)

Price($)	Vol.	No.
$288.96	1858	1

View Market Depth

No.	Vol.	Price($)
2	22	288.000
1	59	287.520
1	35	287.500
1	10	287.010
3	39	287.000

Price($)	Vol.	No.
289.000	40	1
289.650	100	1
289.750	100	1
289.760	55	1
289.790	200	1

Last trade - 16.10pm 04/10/2024 (20 minute delay)

CSL (ASX) Chart

Ann: Appendix 4D and Half Year Accounts, page-23

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4D and Half Year Accounts, page-23

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News